The hypoxic tumor microenvironment is associated with malignant progression and poor treatment response. The
glucose transporter Glut-1 is a prognostic factor and putative
hypoxia marker. So far, studies of Glut-1 in
cancer have utilized conventional immunohistochemical analysis in a series of individual biopsy or surgical specimens. Tissue microarrays, however, provide a rapid, inexpensive means of profiling
biomarker expression. To evaluate
hypoxia markers, tissue cores must show the architectural features of
hypoxia; i.e. viable tissue surrounding necrotic regions. Glut-1 may be a useful
biomarker to validate tissue microarrays for use in studies of
hypoxia-regulated genes in
cancer. In this study, we carried out immunohistochemical detection of
Glut-1 protein in many
tumor and normal tissue types in a range of tissue microarrays. Glut-1 was frequently found in peri-necrotic regions, occurring in 9/34
lymphomas, 6/12
melanomas, and 5/16
glioblastomas; and in 43/54 lung, 22/84 colon, and 23/60 ovarian
tumors. Expression was rare in breast (6/40) and prostate (1/57)
tumors, and in normal tissue, was restricted to spleen, tongue, and CNS endothelium. In conclusion, tissue microarrays enable the observation of Glut-1 expression in peri-necrotic regions, which may be linked to
hypoxia, and reflect previous studies showing differential Glut-1 expression across
tumor types and non-malignant tissue.